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Despite improvements in the prognosis
of childhood acute lymphoblastic leuke-
mia (ALL), subgroups of patients would
benefit from alternative treatment ap-
proaches. Our aim was to identify genes
with DNA methylation profiles that could
identify such groups. We determined the
methylation levels of 1320 CpG sites in
regulatory regions of 416 genes in cells
from 401 children diagnosed with ALL.
Hierarchical clustering of 300 CpG sites
distinguished between T-lineage ALL and
B-cell precursor (BCP) ALL and between
the main cytogenetic subtypes of BCP
ALL. It also stratified patients with high
hyperdiploidy and t(12;21) ALL into 2 sub-
groups with different probability of re-
lapse. By using supervised learning, we
constructed multivariate classifiers by ex-
ternal cross-validation procedures. We
identified 40 genes that consistently con-
tributed to accurate discrimination be-
tween the main subtypes of BCP ALL and
gene sets that discriminated between sub-
types of ALL and between ALL and con-
trols in pairwise classification analyses.
We also identified 20 individual genes
with DNA methylation levels that pre-
dicted relapse of leukemia. Thus, methyl-
ation analysis should be explored as a
method to improve stratification of ALL
patients. The genes highlighted in our
study are not enriched to specific path-
ways, but the gene expression levels are
inversely correlated to the methylation
levels. (Blood. 2010;115:1214-1225)
Introduction
Acute lymphoblastic leukemia (ALL) is the most common form of
childhood cancer. Currently, ALL is classified into genetic subtypes
according to cytogenetically defined chromosomal aberrations, of
which the most frequent in B-cell precursor leukemia (BCP ALL)
are the translocations ETV6/RUNX1, that is, t(12;21)(p13;q22),
E2A/PBX1, that is, t(1;19)(q23;p13), and BCR/ABL, that is,
t(9;22)(q34;q11); high hyperdiploidy (HeH); and rearrangement of
the MLL gene on chromosome region 11q23.1 These large-scale
genetic aberrations are important hallmarks and valuable for
guiding the treatment of BCP ALL patients. T-lineage ALL
(T-ALL) is characterized by cryptic rearrangements in multiple
genomic regions, including the T-cell receptor gene regions on
chromosomes 14q11 and 7q32 in approximately one-half of
the cases.2,3
In addition to large-scale chromosomal aberrations, other
molecular mechanisms are likely to contribute to the conversion of
lymphocyte progenitor cells into leukemic cells.4 DNA methyl-
ation, which occurs most frequently at cytosine residues in CpG
sites, plays an important role both in the control of chromatin
structure and of gene expression. Methylation of CpG sites in
promoter regions of genes regulates their expression by alteration
of chromatin structure or by direct interactions between CpG sites
and transcription factors. Perturbation of DNA methylation could
be one of the molecular mechanisms underlying leukemia.
In early studies investigators5,6 have obtained promising results
in the use of hypermethylation of CpG sites in individual candidate
genes as biomarkers for the identification of subgroups of child-
hood ALL and prognosis of disease progression. More recently,
large-scale methylation analyses have identified methylation pro-
files that distinguish ALL cells from normal cells7,8 and from the
other leukemia cell types: AML,9 CLL, and MCL.10 Moreover, the
methylation status of a single gene, DDX51, was found to
differentiate patients with B-cell and T-cell ALL.8 Aberrant methyl-
ation of CpG sites in the promoter regions of genes in leukemia cell
lines or primary ALL cells has been found to correlate with the
expression of individual genes.7-9
So far, genome-wide profiling of DNA methylation has relied
on indirect methods, such as use of methylation-sensitive enzymes,
which yield data only on a reduced representation of CpG sites in
the genome.11 An alternative approach is to use direct hybridization
with tiling probes that target the CpG sites in the entire genome for
unbiased detection of methylated CpG sites. The high costs of
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genome-wide oligonucleotide microarrays prohibit their use in
large sample sets.12 Consequently, studies on DNA methylation in
ALL have been limited by incomplete representation of the
analyzed CpG sites and by a small number of samples included in
the analysis.7-10 Genome-wide gene expression studies have been
more successful in the identification of gene sets that could be used
as ALL subtype classifiers and as prognostic markers.13-19
In a recent genome-wide survey of 8000 genes in 197 bone
marrow or blood samples from children diagnosed with ALL in the
Nordic countries,20 we identified 400 genes that displayed imbal-
anced allele-specific expression (ASE). ASE indicates that the
expression of these genes is regulated by cis-acting factors, of
which DNA methylation that silences gene expression could be
one. For a subset of these genes we demonstrated a quantitative
correlation between ASE and CpG site methylation of gene
promoter regions.20 In the present study the methylation status of
1320 CpG sites in the genes that displayed ASE in our previous
study were determined by the use of a quantitative methylation
assay in 401 ALL samples, including the 197 samples analyzed in
our previous study. Our aim was to identify genes in which CpG
site methylation would allow the classification of ALL subtypes
and predict the response to treatment and clinical outcome of
the patients.
Methods
Patient samples
Bone marrow or peripheral blood samples from 401 children (235 boys and
166 girls) diagnosed with ALL were included in the study. A total of 388 of
the children were enrolled on the Nordic Society of Pediatric Hematology
and Oncology ALL 1992 or ALL 2000 treatment protocol during 1996 to
2006.21 Thirteen patients younger than 1 year of age were treated according
to the Interfant99 protocol.22 The Ethics Committee of Uppsala University
approved the study, and the patients and/or their guardians provided written
informed consent. The study was conducted in accordance with the
Declaration of Helsinki. The clinical characteristics of the patients,
including immunophenotypes and chromosomal aberrations, are listed in
Table 1. Clinical follow-up data were retrieved from the Nordic registry at
the Childhood Cancer Research Unit in Stockholm, with the last follow-up
in March 2009. The median follow-up time for surviving patients was
6.4 years (range, 1.6-12.5 years). Fifteen control DNA samples that were
isolated from bone marrow identically as the DNA samples from ALL
patients were included as control samples.
The cell samples were collected in heparinized tubes before treatment
and shipped to the laboratory in Uppsala within 24 to 36 hours. Leukemic
cells were isolated by 1.077 g/mL Ficoll-Isopaque (Pharmacia) density-
gradient centrifugation. The proportion of leukemic cells was estimated on
May-Gru¨nwald-Giemsa–stained cytocentrifugate preparations by the use of
light microscopy. The cell samples selected for analysis contained at least
90% lymphoblasts after separation. Pellets of 2 to 10 million cells were
immediately frozen and stored at 70°C in established tissue banks at
Uppsala University Hospital following institutional guidelines.
DNA extraction and sodium bisulfite treatment
DNA was extracted from samples containing 2 to 10 million cells by the use
of the AllPrep DNA/RNA Mini Kit (QIAGEN) or the QIAamp DNA Blood
Mini Kit (QIAGEN). The DNA was eluted twice in 100 L of elution buffer
(QIAGEN) and quantified by the use of the NanoDrop ND-1000 UV-Vis
spectrophotometer (NanoDrop Technologies). Between 600 and 750 ng of
DNA was treated with sodium bisulfite by use of the protocol and reagents
from the EZ-96 DNA Methylation Kit (Zymo Research). The modified
DNA was eluted in 12 L of elution buffer and stored at 70°C until use.
A whole-genome–amplified DNA sample, where all CpG sites are unmeth-
ylated, and a DNA sample treated with SssI methyltransferase to methylate
all CpG sites were used as negative and positive controls in the
methylation assay.
Analysis of DNA methylation
A custom-designed GoldenGate methylation analysis panel (Illumina Inc)23
was used for the analysis of 1536 CpG sites located 2 kb upstream to 1 kb
downstream of the transcription start site in 416 genes. The GoldenGate
methylation assay is based on genotyping of C/U polymorphisms, which
Table 1. Clinical characteristics of the ALL samples
BCP ALL T-ALL
Number of patients 341 60
Male/female quotient 1.21 4.0
Median age, y (range) 4.8 (0.03-17.7) 9.7 (1.3-17.5)
WBC, 109/L*
Less than 10 155 (46%) 8 (13%)
10 to less than 50 119 (35%) 11 (18%)
50 or more 62 (18%) 41 (68%)
Missing 5 (1%)
Cytogenetic abnormality†
High hyperdiploidy 104 (30%)
t(12;21) 73 (21%)
Other clonal abnormality 55 (16%)
Normal finding 28 (9%)
MLL/11q23 20 (6%)
No result 18 (5%)
t(1;19) 16 (5%)
t(9;22) 11 (3%)
dic(9;20) 8 (2%)
icamp(21) 6 (2%)
Hypodiploidy 2 (0.6%)
Treatment protocol‡
NOPHO ALL SR 91 (27%)
NOPHO ALL IR 139 (41%)
NOPHO ALL HR 98 (29%) 60 (100%)
Interfant99 13 (4%)
Events
Resistant disease 2 4
Induction death 6 4
Death in CCR 6 4
Second malignancy 5 0
Relapse 69 13
CCR 253 35
Median follow-up, mo (range) 74 (19-153) 75 (27-154)
p-DFS§ (SE)
3 y 0.82 (0.02) 0.67 (0.06)
5 y 0.76 (0.03) 0.67 (0.06)
p-OS (SE)
3 y 0.89 (0.02) 0.62 (0.07)
5 y 0.85 (0.03) 0.62 (0.07)
SR indicates standard risk; IR, intermediate risk; HR, high risk; p-DFS, predicted
disease-free survival; and p-OS, predicted overall survival.
*White blood cell count at diagnosis (109/L).
†The diagnosis was established at a pediatric oncology center by analysis of
bone marrow aspirates with respect to morphology, immunophenotype, and cytoge-
netics of the leukemic cells. Fluorescence in situ hybridization and/or reverse-
transcriptase polymerase chain reaction were applied to identify t(12;21), t(1;19),
11q23, dic(9;20)(p11-13;q11), and icamp(21q22). High hyperdiploidy (HeH) was
defined as a modal number more than 50 chromosomes. Immunophenotypes were
defined according to the European Group for the Immunological Characterization of
Leukaemias. Chromosome banding of bone marrow and/or peripheral blood samples
were performed using standard methods. The definition and description of clonal
abnormalities followed the recommendations of International System for Human
Cytogenetic Nomenclature. Karyotypes were centrally reviewed.
‡The NOPHO ALL 92 and NOPHO ALL 2000 protocols were used, and their risk
group classification was very similar.
§p-DFS is predicted disease-free survival, defined as time to relapse, death in
CCR or second malignancy.
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appear as a result of the conversion of unmethylated C-nucleotides into
U-nucleotides by bisulfite treatment. The genotyping assay uses allele-
specific primers, which are extended with dNTPs and ligated to locus-
specific oligonucleotides. The ligated products are then amplified by the use
of PCR with fluorescently labeled universal primers in a 1536-plex reaction
and captured by hybridization to BeadArrays.24 The fluorescence signals
were measured from the BeadArrays by the use of an Illumina BeadStation
GX scanner. The fluorescence data were then analyzed by the use of the
BeadStudio software (Illumina Inc), which assigns a quantitative measure
of the methylation levels (beta value) for each CpG site, that corresponds to
the ratio between the fluorescence signal from the methylated allele (C) and
the sum of the fluorescent signals of the methylated (C) and unmethylated
(U) alleles. The beta values range from 0 to 1.0, which corresponds to no
methylation of either allele to complete methylation of both alleles.
For quality control of the methylation data, an equation implemented in
the BeadStudio software was used to calculate a detection P value, which
describes the chance that a signal from a target CpG site is distinguishable
from that from the negative controls. A detection P value greater than 0.05
in more than 50 samples was used as a cutoff, whereby 216 CpG sites were
excluded from further analysis. The remaining 1320 CpG sites with
high-quality data were used for the analysis. The negative and positive
control samples had median beta values of 0.07 and 0.79, respectively,
across all CpG sites that passed the quality control filter.
The performance of the GoldenGate methylation assay was validated by
replicating the bisulfite treatment and subsequent CpG site methylation
analysis in 21 samples. The concordance between replicate assays across
the 300 variable CpG sites selected for analysis was high, with a median
Pearson correlation coefficient R 0.90 for pairwise sample comparisons.
The corresponding correlation coefficient was R 0.93 for pairwise CpG
site comparisons across the 21 replicate samples (supplemental Figure 1
and supplemental Table 1, available on the Blood website; see the
Supplemental Materials link at the top of the online article). In addition, the
methylation levels of CpG sites determined by the GoldenGate assay were
validated in 5 genes in 8 samples by standard Sanger sequencing. With the
use of the median beta values for the positive and negative control samples
as cutoff values for complete methylation (C) and no methylation (T  U),
concordant results for the methylation status determined by both methods
were obtained for 87% of the observations (supplemental Figure 2). More
details and data from the validation experiments are available as supplemen-
tal Methods and supplemental Figure 2.
Determination of total gene expression levels
The ASE data from our previous study, in which we genotyped 11 000 SNPs in
exon-coding regions of 8000 genes in 197 ALL samples by using Illumina
BeadArray technology,20 were converted to total gene expression levels by
summing the mean fluorescence signals for the 2 SNP alleles measured in
triplicate assays. In this calculation we included both the samples that were
heterozygous at the indicator SNPs used to score ASE and the samples that
were homozygous at the indicator SNPs. To correct for possible differences
in signal intensities between samples caused by technical factors, such as
amount and quality of RNA analyzed, the sum of the fluorescent signals
from the 2 SNP alleles for each gene was quantile normalized across the
samples before analysis.25
Data analysis and statistical methods
The data analyses were performed by the use of programs written in R,26
applying the “cluster” and “survival” packages and standard functions.
Unsupervised hierarchical clustering was performed by the use of conven-
tional agglomerative clustering (using “hclust”) with one minus the
correlation coefficient as the similarity measure for pairs of individuals and
average linkage as the measure of cluster similarity. The “diana” algorithm
was applied for “divisive” hierarchical clustering to divide the ALL samples
into 2 groups according to similarities in their methylation patterns. This
algorithm performs the clustering by a divisive (top-down) procedure, in
which the whole dataset is iteratively divided into smaller parts. Outcome
analyses were performed with consideration of competing risks by the use
of the Gray test to assess differences between groups27 and the Fine and
Gray proportional hazards model for univariate and multivariate analyses of
potential prognostic factors.28 Pearson correlation coefficients were calcu-
lated for DNA methylation and total gene expression levels. Ingenuity
Pathway Analysis (Ingenuity Systems Inc) was applied to gene sets
identified by the methods described previously.
For the multivariate classification analyses, nearest shrunken centroids
(NSCs) classifiers29 were designed as part of an external 10-fold cross-
validation procedure.30 In each fold the shrinkage parameter of the NSC
classifier was chosen to minimize the internal 10-fold cross-validation error.
To determine the significance of the classification results obtained, this
double-loop cross-validation procedure also was used 1000 times, with
permuted class labels for the design examples. The implementation was
performed by means of the R-package “pamr” (http://cran.r-project.org)
combined with a modified version of the module for external cross-
validation.31 CpG sites ranked among the top 80% in each fold were
visualized by biclustering with the CpG sites along one dimension and the
patient samples along the other. For the visualization, divisive hierarchical
clustering that uses the Euclidean distance metric and the “diana” algo-
rithm32 as implemented in the R-package was used. More details on the
multivariate classification procedure are available as supplemental Methods
and supplemental Table 4.
Results
Selection of CpG sites
We determined the methylation status of the promoter regions of
416 genes in bone marrow or peripheral blood samples from
401 children with ALL. Of the genes included in the analysis,
391 genes were selected because in a previous study20 they
displayed ASE in a subset of the ALL samples analyzed here. We
also included 10 candidate genes on the basis of previous studies on
methylation in ALL8,10,33-35 and 15 genes reported to be functional
or marker genes in ALL.36-41 By using the quantitative GoldenGate
assay, we measured the methylation levels of 1320 CpG sites in
these genes. Supplemental Table 2 provides the complete set of
data from this analysis and indicates which of the genes were
selected on the basis of ASE and which from the literature,
respectively. We detected consistently lower methylation levels for
CpG sites located within CpG islands, which are regions of at least
200 bp in size with increased GC content than in CpG sites outside
CpG islands (Table 2). CpG sites outside CpG islands also
exhibited significantly more variation in methylation levels than
CpG sites within CpG islands (Figure 1). We reasoned that CpG
sites with variation in their methylation levels between ALL
samples are potentially most informative as markers for classifica-
tion of ALL. Therefore, we selected CpG sites that displayed high SDs
( 0.16) combined with a wide range distribution (0.73-0.95) for the
beta values across all ALL samples for analysis. Variable CpG sites
located close to each other with similar methylation patters were
excluded to avoid redundancy and to reduce the number of tests to be
performed. On the basis of these considerations, we included
300 variable CpG sites located in 189 genes for further analysis
(supplemental Table 2).
DNA methylation profiles in ALL subtypes
Table 2 shows that the median methylation levels of the 300
selected variable CpG sites were greater in the ALL samples than in
15 nonleukemic control samples (P  .001) and that the ALL
samples with the BCP immunophenotype had lower median
methylation levels than the T-ALL samples (P  .001). We then
used the 300 selected CpG sites for unsupervised hierarchical
clustering of the 401 ALL samples included in our study. The
dendrogram in Figure 2 demonstrates that this analysis clearly
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separates the samples from patients with T-ALL and BCPALL. The
methylation patterns of the CpG sites also allowed distinction
between the main cytogenetic subtypes of BCP ALL, that is, HeH,
t(12;21), 11q23, and t(1;19). A total of 7 of 8 samples with
dic(9,20) clustered with other clonal abnormalities, 4 of the
6 samples with icamp(21) clustered in the HeH group, and 11
samples with t(9;22) clustered in the center of the dendrogram in a
mixed group of samples. Samples with other clonal abnormalities
and normal cytogenetic findings were scattered and interspersed
with other subtypes.
DNA methylation and clinical outcome in HeH and t(12;21) ALL
In an effort to identify ALL patients with differences in clinical
outcome depending on their DNA methylation patterns, we used
the 300 variable CpG sites for further hierarchical clustering of the
samples in the 3 largest subtypes T-ALL, t(12;21), and HeH into
2 separate and distinct groups (Figure 3). Evaluation of the clinical
information of the patients in these groups revealed a difference in
the probability of relapse between the 2 HeH groups. There was
only 1 relapse among the 31 patients in group 1 compared with
15 relapses among the 73 patients in group 2 (P  .030; Figure 3
top right). There was also a difference in the probability of relapse
between the 2 t(12;21) subgroups, with no relapse among the
22 patients in group 1 compared with 11 relapses among the
51 patients in group 2 (P  .032; Figure 3 middle right). There was
no difference in the probability of relapse between the 2 T-ALL
subgroups defined by their DNA methylation status in the divisive
cluster analysis.
The white blood cell (WBC) count at diagnosis and the
prevalence of the classical trisomies of chromosomes X, 4, 6, 10,
14, 17, 18, and 21 were similar in the 2 HeH subgroups. The
median modal number of chromosomes was also similar, with
55 and 56 in groups 1 and 2 in Figure 3, respectively. In regression
analysis, including age, sex, and WBC at diagnosis as covariates,
DNA methylation defined a cohort (HeH group 2 in the top right of
Figure 3) with increased risk of relapse with a relative risk of 6.4
(95% confidence interval, 0.89-0.47; P  .066). None of the other
factors had an independent prognostic impact (P  .3). Early
treatment response was not included in this model because data on
minimal residual disease were available for less than 50% of the
patients, and all but 1 patient in each cluster group had less than 5%
of blast cells (M1) in their bone marrow after induction therapy. As
shown in supplemental Table 3, there were few other events than
relapse among the patients. The t(12;21) subgroup with favorable
prognosis had lower WBC count at diagnosis than the group with
less favorable prognosis (P  .003, data not shown), but there was
no difference in the frequency of del(12)(p13p13) or der(21)t(12,21).
In the multivariate regression analysis, only WBC had independent
prognostic impact (P .001), with a trend value for age (P .064).
Table 3 lists the genes that displayed a median CpG site
methylation difference of 0.3 or greater between the samples in the
2 HeH groups (37 CpG sites in 30 genes) and the 2 t(12;21) groups
(34 CpG sites in 27 genes). Sixteen of these genes (COBL,
COL6A2, CPVL, DFNB31, EYA4, FAM24B, FAT1, FUCA2, INADL,
MYO3A, PCDHGA12, PON3, ROR1, SYNM, TNIK, and ZNF502)
were common for both cytogenetic subtypes. Interestingly, all but
1 of the 37 most variable CpG sites in the HeH subtype and all of
the 34 most variable CpG sites in the t(12;21) subtype had a greater
median methylation level in the group of patients (groups 1 in top
and middle right panels of Figure 3) with better prognosis.
Multivariate classification of ALL subtypes with DNA
methylation patterns
To identify genes with DNA methylation patterns that would
allow discrimination between cytogenetic subtypes of ALL, we
used the methylation data from the 300 selected CpG sites to
design NSC classifiers in an external 10-fold cross-validation
procedure. In each fold, nine tenths of the samples were used for
classifier design, and one tenth of the samples were used to
estimate the performance. In 2 separate experiments, we first
applied this procedure for discrimination between the 213
samples belonging to the HeH, t(12;21), 11q23, or t(1;19)
subtypes of BCP ALL and between the 401 samples in the BCP
ALL and T-ALL groups, respectively (see Table 1). Table 4
illustrates the excellent performances of the classifiers obtained
in both experiments. The permutation results confirm that it is
unlikely (P  .001) to obtain the individual class accuracies by
chance. The number of CpG sites selected for classification of
the BCP ALL subtypes varied from 82 to 110 (median, 103)
between folds. After filtering out the CpG sites that were not
among the 80% top ranked sites in each of the 10 folds, the
classifier selected 60 CpG sites located in 40 genes for
classification of the BCP ALL subtypes. We used the methyl-
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Figure 1. Comparison of the variability in methylation levels between CpG sites
located within or outside CpG islands. The SDs for methylation levels measured
for 1320 CpG sites across 401 ALL samples (529 320 observations) are shown on the
horizontal axis. The vertical bars show the proportion of the observations in each bin
of SD in methylation level. The graph shows that CpG sites outside CpG islands have
greater variability in methylation levels between samples than CpG sites within CpG
islands (P  .001).
Table 2. Overview of CpG site methylation in the ALL samples
Median methylation (range)
P*
Median methylation (range)
P†ALL (n  401) Nonleukemic (n  15) BCP ALL (n  341) T-ALL (n  60)
All CpG sites (n  1320) 0.18 (0.04-0.61) 0.12 (0.08-0.13)  .001 0.17 (0.04-0.46) 0.26 (0.11-0.61)  .001
Within CpG islands (n  726) 0.07 (0.02-0.2) 0.05 (0.03-0.05)  .001 0.07 (0.02-0.2) 0.07 (0.03-0.2) .320
Outside CpG islands (n  594) 0.65 (0.34-0.84) 0.59 (0.55-0.63)  .001 0.64 (0.34-0.84) 0.72 (0.62-0.83)  .001
Highly variable (n  300) 0.34 (0.07-0.84) 0.19 (0.14-0.27)  .001 0.32 (0.07-0.67) 0.54 (0.25-0.84)  .001
BCP indicates B-cell precursor ALL.
*P value for the difference in median methylation between ALL patients and controls.
†P value for the difference in median methylation between BCP ALL patients and T-ALL patients.
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ation levels of these 60 CpG sites for hierarchical biclustering of
the patient samples (Figure 4), which revealed distinct methyl-
ation differences between the 4 subtypes of BCP ALL. For
discrimination between samples from patients with BCP ALL
and T-ALL the classifier selected 9 CpG sites located in the
CAPSL, CD300LF, GBE1, KIAA1462, MYBPC2, PECAM1,
SDCBP2, SEC31B, and SLC22A18 genes that passed the 80%
rank filter. SDCBP2 was the only one of these genes that was
also among the 40 genes for classification of BCP ALL subtypes.
Hierarchical biclustering by the use of these CpG sites revealed
consistently high methylation levels in T-ALL samples and low
methylation levels in the BCP ALL samples for the selected
genes (supplemental Figure 3).
In addition to the 2 aforementioned analyses, we performed 12
pairwise experiments by using NSC classifiers, as described in the
supplemental Materials and supplemental Table 4. The classifier
selected additional genes with methylation patterns that discrimi-
nate between pairs of HeH, t(12;21), 11q23, or t(1;19) subtypes and
between control cells and the ALL subtypes (supplemental Figure
3). Most of the genes (36 of 40) that emerged from the simulta-
neous classification of the 4 major subtypes of BCP ALL were also
highlighted in the pairwise classification experiments for BCPALL
subtypes, together with 25 additional genes. Twelve genes that
were not selected by the classifier for distinction between ALL
subtypes emerged in the analysis involving the control cells.
A summary of the CpG sites and genes highlighted by each of the
14 NSC classification experiments can be found in supplemental
Table 5. The genes with differential methylation profiles between
T-ALL and BCP ALL and subtypes of BCP ALL identified by the
multivariate classification method represent promising candidate
markers for subtyping ALL patients by the use of DNA methylation
analysis.
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Figure 2. Hierarchical clustering to separate ALL subtypes by methylation profiles. Unsupervised hierarchical clustering was performed by the use of beta values for the
300 selected CpG sites as the distance metric and average linkage as the clustering method, including all study samples. In the dendrogram each individual sample is
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Correlation between CpG site methylation in individual genes
and clinical outcome
We also explored dependencies between the methylation level of
CpG sites in individual genes and clinical outcome in the
samples from T-ALL and BCP ALL patients. Univariate regres-
sion analysis highlighted 22 CpG sites in 20 genes, for which the
methylation levels correlated with risk of relapse in the patients
with a nominally significant P value less than .01 (Table 5). To
visualize the dependencies between CpG site methylation and
probability of relapse, we divided the samples into 3 groups on
the basis of beta values, which roughly correspond to putatively
no methylation, methylation of 1 allele, or methylation of both
alleles at a CpG site. Figure 5 shows relapse curves for CpG
sites in the RUNDC3B, ENSG00000167210, and SPON2 genes
with strong correlations between CpG methylation and clinical
outcome in patients with BCP ALL, and in the LRP1B gene in
patients with T-ALL. The relapse curves for all 22 CpG sites
with a regression P less than .01 according to the Fine and Gray
test are presented in supplemental Figure 5. The presented P
values are unadjusted for multiple testing. Hence, these results
should be viewed as preliminary. Of the 20 genes identified here,
8 genes (CHST13, COBL, CPVL, EVC, LRP1B, PAX8,
PCDHGA12, and SPON2) were also among the top genes
highlighted by “divisive” hierarchical clustering (Table 3). High
methylation levels correlated with favorable prognosis of the
disease for these individual genes, with the exception of
CHST13.
Gene functions
Ingenuity Pathway Analysis did not show statistically signifi-
cant enrichment to specific pathways for the gene sets selected
by the NSC classifier or genes in which the methylation patterns
correlated with relapse of ALL. However, many of the genes
encode proteins that are involved in key cellular functions like
adhesion, apoptosis, proliferation, and growth (supplemental
Table 6). For 47 of the 99 genes that emerged in the different
parts of our study for which both methylation and gene
expression data were available, we observed a clear inverse
correlation (permuted P  .001) between CpG site methylation
levels and gene expression levels (supplemental Table 7). For
these genes, 7% to 77% (median, 23%) of the variation in gene
expression levels between samples is explained by CpG site
methylation. Given that these genes were originally included in
our study because they displayed ASE and that we selected
variable CpG sites for analysis, it is not unexpected that genes
with an inverse correlation between CpG site methylation and
gene expression levels are overrepresented among the genes
highlighted in our study (Figure 6).
Discussion
In the present study we analyzed the DNA methylation patterns
of 416 genes in a large collection of childhood ALL samples.
The majority of the genes (n  391) included in our analysis
were selected on the basis of the results of a survey of ASE of
8000 genes20 in approximately one half of the ALL samples
analyzed here. Our hypothesis when selecting these genes was
that CpG site methylation in gene promoter regions is 1 of the
cis-acting factors that leads to ASE by silencing the expression
of 1 of the alleles. In contrast with earlier studies7,8,10 that have
focused on analysis of methylation in CpG islands, our custom-
designed array also included CpG sites located outside CpG
islands within 2 kb upstream to 1 kb downstream of the
transcription start site. Our selection of CpG sites was advanta-
geous because CpG sites in these regions had greater overall
methylation levels and greater variation in their methylation
levels than CpG sites located within CpG islands. These findings
are in agreement with a recent study, which found that most
cancer- and tissue-specific methylation is located outside CpG
islands up to 2 kb upstream of the transcription start sites
of genes.42 The study found that the differentially methyl-
ated regions were frequently associated with alternative trans-
cription start sites, suggesting a role for the CpG sites in these
regions in the regulation of gene expression. In accordance
with this suggestion, our study highlighted genes with a
remarkable inverse correlation between CpG site methylation
and expression.
An advantage of our study is that it included a large number
of samples from clinically well-characterized ALL patients.
Among the 401 ALL patients, most cytogenetic subgroups of
HeH BCP ALL
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Figure 3. Refined hierarchical clustering of ALL samples in the HeH and t(12,21)
BCP ALL and T-ALL subgroups by methylation profile and analysis of probabil-
ity of disease relapse. (Left) Dendrograms from divisive (top-down) hierarchical
clustering by use of the Euclidean distance between beta values for the 300 selected
CpG sites as distance metric. In the dendrogram each individual sample is
represented by a black or gray horizontal bar. (Right) Probability of relapse
(p-relapse) for the patients in group 1 and group 2 (Gray test). The p-relapse is given
on the y-axis and the observation time in months on the x-axis. The P values for the
difference in p-relapse between group 1 and group 2 are shown in the panels (Gray
test). The total number of different events in the 2 groups of patients with HeH and
t(12;21) ALL are shown in supplemental Table 3. The number of events for the
patients with T-ALL is given in Table 1.
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Table 3. CpG sites with largest variation in methylation levels between subgroups of high hyperdiploidy and t(12;21) samples
with different prognosis
Gene* CpG site location†
Median methylation level
Difference
M-W¶
Group 1‡ Group 2§ P
High hyperdiploidy
FAAH 1 46 632 681 0.72 0.09 0.63  .001
ZNF502 3 44 729 363 0.81 0.23 0.58  .001
PCDHGA12 5 140 790 293 0.67 0.14 0.53  .001
TNIK 3 172 661 831 0.59 0.08 0.51  .001
SPATA6 1 48 709 977 0.81 0.31 0.50  .001
PDLIM5 4 95 592 393 0.56 0.06 0.50  .001
DSC3 18 26 876 433 0.70 0.21 0.49  .001
PLXDC2 10 20 144 578 0.66 0.18 0.47  .001
ZNF462 9 108 663 645 0.77 0.29 0.47  .001
EVC 4 5 763 453 0.62 0.16 0.46  .001
FUCA2 6 143 874 555 0.56 0.11 0.44  .001
INADL 1 61 980 382 0.52 0.11 0.41  .001
ROR1 1 64 012 296 0.77 0.36 0.41  .001
COL6A2 21 46 342 715 0.85 0.44 0.41  .001
COL6A2 21 46 343 270 0.82 0.43 0.39  .001
PLXDC2 10 20 144 911 0.43 0.04 0.39  .001
DSC3 18 26 876 092 0.64 0.25 0.39  .001
INADL 1 61 980 822 0.51 0.13 0.38  .001
SLC22A18 11 2 877 055 0.19 0.57 -0.38  .001
FAT1 4 187 881 370 0.79 0.41 0.38  .001
PCLO 7 82 629 511 0.51 0.13 0.37  .001
RYR3 15 31 390 014 0.48 0.10 0.37  .001
SYNM 15 97 462 801 0.41 0.05 0.37  .001
DFNB31 9 116 306 640 0.53 0.17 0.37  .001
DSC3 18 26 876 558 0.69 0.32 0.36  .001
EYA4 6 133 603 412 0.60 0.24 0.36  .001
NKAIN4 20 61 357 043 0.45 0.10 0.35  .001
SEC14L4 22 29 231 446 0.61 0.26 0.35  .001
AGAP1 2 236 066 870 0.45 0.12 0.33 .005
FAM24B 10 124 629 293 0.51 0.19 0.32  .001
PON3 7 94 864 117 0.48 0.16 0.32  .001
EYA4 6 133 604 919 0.64 0.32 0.32  .001
CARKD 13 110 066 706 0.48 0.16 0.32  .001
CPVL 7 29 152 529 0.44 0.12 0.32  .001
FAT1 4 187 881 106 0.63 0.32 0.30  .001
MYO3A 10 26 262 977 0.51 0.21 0.30  .001
COBL 7 51351023 0.55 0.25 0.30  .001
t(12;21)
SYNM 15 97 462 801 0.80 0.15 0.65  .001
FAT1 4 187 881 370 0.64 0.07 0.56  .001
FAT1 4 187 881 106 0.72 0.21 0.51  .001
PON2 7 94 902 405 0.69 0.19 0.50  .001
FUCA2 6 143 874 555 0.62 0.14 0.48  .001
DFNB31 9 116 306 640 0.63 0.17 0.46  .001
ZNF667 19 61 681 253 0.51 0.07 0.45 .006
CELSR1 22 45 312 662 0.63 0.18 0.44  .001
SPON2 4 1 155 890 0.56 0.13 0.44  .001
LRP1B 2 142 605 338 0.67 0.23 0.44  .001
COL6A2 21 46 343 270 0.56 0.16 0.40  .001
PAX8 2 113 752 043 0.52 0.13 0.39  .001
TNIK 3 172 661 831 0.69 0.30 0.39  .001
INADL 1 61 980 822 0.66 0.27 0.39  .001
CELSR1 22 45 311 948 0.87 0.47 0.39  .001
ZNF667 19 61 680 438 0.50 0.12 0.38 .014
MYO3A 10 26 263 527 0.72 0.35 0.37  .001
ROR1 1 64 012 296 0.69 0.32 0.37  .001
EYA4 6 133 603 412 0.79 0.43 0.36  .001
INADL 1 61 980 382 0.81 0.44 0.36  .001
PON3 7 94 864 117 0.65 0.29 0.36  .001
CPVL 7 29 152 529 0.84 0.50 0.34  .001
ZNF502 3 44 729 363 0.88 0.55 0.33  .001
GEFT 12 56 290 675 0.72 0.39 0.33  .001
(continued)
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ALL were represented by multiple samples. We describe here,
for the first time, significant differences in methylation patterns
between BCP and T-ALL and between subgroups of BCP ALL
identified by the use of hierarchical clustering. For the first time,
we also describe promising results by using carefully validated
supervised learning for classification of ALL subtypes on the
basis of methylation patterns. Although we did not analyze the
same ALL subtypes as a previous study that used a similar
supervised learning procedure for mRNA expression15 as we
used here, the performance levels of the classifiers are compa-
rable between the 2 studies. Our results show that a 40-gene
methylation profile accurately discriminates between 4 subtypes
of BCP ALL and that additional CpG site methylation profiles
of 2 to 43 genes discriminate between T-ALL and BCP ALL
and between subgroups of BCP ALL in pairwise analyses.
We observed that within subtypes, multiple genes have
highly similar methylation patterns in an ALL subtype, although
they are located on different chromosomes. This observation,
combined with our finding of a strong inverse correlation
between methylation and expression levels, is consistent with
the formation of interchromosomal networks that are subject to
joint epigenetic mechanisms regulating gene expression.43
Our findings should be confirmed in an independent patient
cohort to explore methylation analysis as an instrument to refine
subgrouping of ALL patients in the clinical setting. Although the
expression levels of genes identified by genome-wide expres-
sion profiling have allowed construction of accurate classifiers
for ALL subtypes,19 a great advantage of methylation analysis is
that DNA, as a more stable molecule than RNA, is used as the
analyte.44 Similar genotyping methods as those already in
routine use for detection of point mutations in clinical laborato-
ries can be used for the analysis of CpG site methylation.
Further analysis of the differences in methylation patterns
between subgroups of ALL in relation to high-resolution data on
copy number alterations might also help to clarify whether
changes in DNA methylation lead to large-scale translocations
and rearrangements or are secondary to these chromosomal
aberrations.45,46
Even more interesting is the potential use of DNA methylation
analysis for stratification of patients with different clinical progno-
sis. We found that divisive hierarchical clustering of patients with
the HeH karyotype defined a subgroup with increased risk for
disease relapse. If confirmed, such data might be useful for
stratification of patients to treatment protocols of different inten-
Table 4. Performance of the multivariate classifier
ALL subtype Sensitivity (%)* Specificity (%)†
Positive predictive
value (%)‡
Negative predictive
value (%)§
Accuracy
(%) P¶
BCP ALL subtypes
11q23 (n  20) 100 (67-100) 100 (95-100) 100 (67-100) 100 (100-100) 100 (95-100)  .001
HeH (n  104) 100 (83-100) 100 (91-100) 100 (91-100) 100 (85-100) 98 (95-100) N/A
t(1;19) (n  16) 100 (100-100) 100 (100-100) 100 (100-100) 100 (95-100) 100 (95-100)  .001
t(12;21) (n  73) 100 (88-100) 100 (92-100) 100 (88-100) 100 (93-100) 100 (90-100)  .001
BCP ALL and T-ALL
BCP ALL (n  341) 100 (97-100) 100 (100-100) 100 (100-100) 100 (86-100) 99 (98-100) N/A
T-ALL (n  60) 100 (86-100) 100 (97-100) 100 (86-100) 100 (100-100) 99 (98-100)  .001
Median values (and 20%-80% percentiles) are given in the table.
TP indicates true positives; FN, false negatives; TN, true negatives; FP, false positives; and N/A, not available (see “Methods”).
*(TP)/(TP  FN).
†(TN)/(FP  TN).
‡(TP)/(TP  FP).
§(TN)/(TN  FN).
(TP  TN)/(TP  TN  FP  FN).
¶Probabilities from 1000 permutations.
Table 3. (continued)
Gene* CpG site location†
Median methylation level
Difference
M-W¶
Group 1‡ Group 2§ P
FAT1 4 187 882 260 0.74 0.41 0.33  .001
PCDHGA12 5 140 790 293 0.83 0.51 0.32  .001
BMP4 14 53 493 485 0.50 0.18 0.32  .001
CHST13 3 127 725 591 0.66 0.35 0.32  .001
NOTCH3 19 15 172 990 0.62 0.31 0.31  .001
ROR1 1 64 013 028 0.60 0.30 0.31 .001
FAT1 4 187 883 295 0.40 0.09 0.30  .001
FAM24B 10 124 629 293 0.40 0.10 0.30 .018
COBL 7 51 351 023 0.55 0.25 0.30  .001
VANGL1 1 115 986 543 0.78 0.48 0.30  .001
*Gene symbol according to HUGO Gene Nomenclature Committee (http://www.genenames.org/).
†Chromosome number and genomic coordinate of the C nucleotide in each CpG site (genome build 36).
‡Median methylation levels for patients in group 1 (Figure 3).
§Median methylation levels for patients in group 2 (Figure 3).
Difference in median methylation levels between patients in group 1 and patients in group 2.
¶Unadjusted Mann-Whitney P value for difference in median methylation between patients in group 1 and patients in group 2.
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Figure 4. Biclustering of ALL patient samples in the 4 main BCP
ALL subtypes according to methylation levels of CpG sites defined
by repeated cross-validation supervised learning for multivariate
classification. Shown is a “heat-map” of the main BCP ALL subtypes by
use of the 60 most informative CpG sites in 40 genes defined by the NSC
classifier. The CpG sites are shown in the vertical columns and the ALL
samples in the horizontal rows. The color code for the BCPALL subtypes
is shown in the bottom left corner of the figure. High methylation levels
are shown in red and low methylation levels in blue, according to the
scale bar below the figure.
Table 5. CpG sites in 22 genes with a correlation between methylation level and clinical outcome in the cell samples from patients with ALL
Gene* CpG site location† Fine & Gray P‡
N Beta value
less than 0.25
N Beta value
0.25 to 0.75
N Beta value
more than 0.75 Gray test P§
B-cell precursor ALL
ENSG00000167210 18 42 434 938  .001 26 170 143 .007
LRP1B 2 142 605 338  .001 210 112 17 .004
RUNDC3B 7 87 096 309  .001 205 133 1 .032
ENSG00000167210 18 42 435 264 .001 87 73 179 .002
PAX8 2 113 752 043 .002 248 80 11 .081
SPON2 4 1 155 890 .003 251 72 16 .008
ENSG00000136315 14 20 457 591 .005 148 158 33 .004
ALDH1L1 3 127 382 460 .006 267 68 4 .119
CPVL 7 29 152 529 .007 185 108 46 .021
MUC4 3 197 023 530 .008 66 258 15 .172
PCDHGA12 5 140 790 293 .010 169 114 56 .087
High hyperdiploidy BCP
PAX8 2 113 752 043 .003 82 20 2 .089
CPNE7 16 88 170 539 .006 2 51 51 .046
COBL 7 51 352 477 .010 74 29 1 .090
t(12;21) BCP
C6orf47 6 31 738 119  .001 3 44 26  .001
RASAL1 12 112 057 868 .002 68 5 0 .140
CHST13 3 127 726 340 .003 9 41 23 .292
EFCAB4A 11 815 712 .004 5 67 1 .298
BDH2 4 104 241 438 .005 18 53 2 .379
CLEC10A 17 6 924 625 .007 6 53 14 .010
EVC 4 5 764 498 .009 7 55 11 .192
T-ALL
LRP1B 2 142 605 854  .001 7 21 32  .001
IGSF3 1 117 013 015 .006 2 29 29 .070
*Gene symbol according to the HUGO Gene Nomenclature Committee (HGNC; http://www.genenames.org/).
†Chromosome number and genomic coordinate of the C nucleotide in each CpG site (genome build 36).
‡Unadjusted P value for relapse from the univariate regression analysis (Fine and Gray test) with methylation levels as independent variable.
§Unadjusted P value from the Gray test of difference in probability of relapse between the three groups with methylation levels below 0.25, between 0.25 and 0.75, or above 0.75.
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sity. Hierarchical clustering of patients with t(12;21) also identified
a group with increased risk of relapse but in a multivariate
regression analysis subgrouping on the basis of DNA methylation
did not have independent prognostic power. However, in an
exploratory survey in which we used the methylation level of
individual genes we identified additional genes for which the
methylation levels correlated with risk for relapse in each of the
main subgroups of ALL, including the t(12;21) and the T-ALL
groups. The gene sets highlighted in both these approaches were
partly overlapping, and for the majority of the genes high methyl-
ation levels correlated with favorable prognosis of the disease. In
the future, methylation data for CpG sites in a selected number of
genes might hopefully be used to design diagnostic tests to stratify
ALL patients within subgroups.
Most of the genes with ASE that were highlighted as
“classifier” or “predictor” genes in our study are novel with no
previously reported connection with ALL, but we also identified
some genes with previously reported roles in ALL. Our study
confirmed previous results for the PCDHGA12, LRP1B, and
PON3 genes that have been shown to have greater methylation
levels in BCP ALL and T-ALL patients than in control pa-
tients.8,10 In our study these genes emerged in the gene set with
favorable prognosis in BCP ALL and contributed to the distinc-
tion between ALL subtypes and between ALL cells and control
cells. Among the genes that we identified as classifier genes by
using methylation analysis, ARHGAP8, DSC3, FAT1, FXYD2,
IGSF3, PCLO, and PON2 have been reported to have expression
patterns that allow classification of ALL subtypes.18
Accordingly, we observed an inverse correlation between
CpG site methylation and expression levels of these genes, with
the exception of ARHGAP8. We found that high methylation
levels of the tyrosine kinase ROR1, which is differentially
expressed in BCP ALL subtypes,47 contributed to a lower
probability of relapse in BCP ALL. The transcriptional regulator
NOTCH3, for which high methylation levels contributed to a
lower probability of relapse in t(12;21) ALL, is overexpressed in
T-ALL cells and has been suggested to interact with IKZF1
(IKAROS) in the leukemogenesis of T-ALL.48 In our study the
expression levels of ROR1 and NOTCH3 were also inversely
correlated with methylation levels. In accordance with the
important cellular functions of the proteins encoded by several
of the genes highlighted in our study, some of them have been
linked with other forms of cancer and hematologic diseases than
ALL (see supplemental Table 6).
In conclusion, by analysis of the methylation patterns of CpG
sites in 416 genes in a large number of samples from clinically
well-characterized ALL patients, we found marked differences
in methylation patterns between subgroups of patients. Even
more intriguing was the finding of a correlation between the
methylation level and clinical outcome within major subgroups
of ALL patients, suggesting that methylation analysis should
be explored as a method to improve stratification of patients. In
the future, it will be important to analyze the biologic roles in
ALL of the differentially methylated genes highlighted in our
study.
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Figure 5. Correlation between methylation levels of CpG sites in the RUNDC3B,
ENSG00000167210, SPON2, and LRP1B genes and clinical outcome of ALL
patients. Probability of relapse (p-relapse) in patients stratified into 3 groups
according to beta values less than 0.25, 0.25 to 0.75, and greater than 0.75 for
methylation of (A) the CpG site in the ENSG00000167210 gene (chr18, position
42 434,938) in patients with BCP ALL; (B) the CpG site in the RUNDC3B gene (chr7,
position 87 096,309) in patients with BCP ALL; (C) the CpG site in the SPON2 gene
(chr4, position 1,155,890) in patients with BCP ALL; and (D) CpG site in the LRP1B
gene (chr2, position 142,605,854) in patients with T-ALL. The p-relapse is given on
the y-axis and the observation time in months on the x-axis. The P values calculated
by the Gray test are given in the panels.
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Figure 6. Overrepresentation of genes with an inverse correlation between CpG site methylation and gene expression levels among genes highlighted in the study.
The Pearson correlation coefficients for the methylation levels and expression levels for (A) all 391 genes analyzed in this study and (B) 99 genes highlighted by methylation
analysis in the study are shown on the horizontal axis, and the numbers of genes in each bin of correlation coefficients are shown on the vertical axis. The thin bars marked in
gray indicate the upper and lower probability limits (P  .01) for random distribution of correlation coefficients according to 10 000 permutations per gene. The histogram shows
that there is an overrepresentation of genes with an inverse correlation between methylation and gene expression levels, which is unlikely to occur by chance, both among all
genes analyzed in the study and the genes highlighted by methylation analysis. A larger proportion of genes highlighted by methylation analysis have an inverse correlation with
the total expression levels (56%) than that of all analyzed genes (33%). The data underlying the histogram is available in supplemental Table 7.
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